Format
Sort by

Send to

Choose Destination

Search results

Items: 17

1.

Allogeneic transplant for FLT3-ITD+ AML: room for improvement.

Perl AE, Luger SM.

Bone Marrow Transplant. 2016 Apr;51(4):508-10. doi: 10.1038/bmt.2016.37. No abstract available.

PMID:
26974268
2.

Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells.

Saleh AM, Taha MO, Aziz MA, Al-Qudah MA, AbuTayeh RF, Rizvi SA.

Cancer Lett. 2016 Jun 1;375(2):199-208. doi: 10.1016/j.canlet.2016.02.028.

PMID:
26916980
3.

Not only TKI! Targeting FLT3-ITD by autophagy.

Marcucci G, Li L.

Blood. 2016 Feb 18;127(7):796-7. doi: 10.1182/blood-2015-09-666560. No abstract available.

PMID:
26893395
4.

Leukemogenic potency of the novel FLT3-N676K mutant.

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.

Ann Hematol. 2016 Apr;95(5):783-91. doi: 10.1007/s00277-016-2616-z.

PMID:
26891877
5.

Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.

Noronha EP, Andrade FG, Zampier C, de Andrade CF, Terra-Granado E, Pombo-de-Oliveira MS; Brazilian Study Group for Childhood Leukaemia..

Blood Cells Mol Dis. 2016 Mar;57:74-80. doi: 10.1016/j.bcmd.2015.12.003.

PMID:
26852660
6.

The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.

Dickson GJ, Bustraan S, Hills RK, Ali A, Goldstone AH, Burnett AK, Linch DC, Gale RE.

Br J Haematol. 2016 Feb;172(4):573-80. doi: 10.1111/bjh.13873.

7.

The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.

Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR, Nomoto K, Zhao N, Konopleva M, Andreeff M.

Cancer Res. 2016 Mar 15;76(6):1528-37. doi: 10.1158/0008-5472.CAN-15-1580.

PMID:
26822154
8.

Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation.

Berman E, Maloy M, Devlin S, Jhanwar S, Papadopoulos E, Jakubowski A.

Leuk Res. 2016 Jan;40:33-7. doi: 10.1016/j.leukres.2015.11.010.

PMID:
26692109
9.

Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.

Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.

Ann Hematol. 2016 Mar;95(4):625-35. doi: 10.1007/s00277-015-2580-z.

PMID:
26692090
10.

High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.

Shiba N, Ohki K, Kobayashi T, Hara Y, Yamato G, Tanoshima R, Ichikawa H, Tomizawa D, Park MJ, Shimada A, Sotomatsu M, Arakawa H, Horibe K, Adachi S, Taga T, Tawa A, Hayashi Y.

Br J Haematol. 2016 Feb;172(4):581-91. doi: 10.1111/bjh.13869.

PMID:
26684393
11.

Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

Li X, Wang A, Yu K, Qi Z, Chen C, Wang W, Hu C, Wu H, Wu J, Zhao Z, Liu J, Zou F, Wang L, Wang B, Wang W, Zhang S, Liu J, Liu Q.

J Med Chem. 2015 Dec 24;58(24):9625-38. doi: 10.1021/acs.jmedchem.5b01611.

PMID:
26630553
12.

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.

Libura M, Giebel S, Piatkowska-Jakubas B, Pawelczyk M, Florek I, Matiakowska K, Jazwiec B, Borg K, Solarska I, Zawada M, Czekalska S, Libura J, Jakobczyk M, Karabin K, Paluszewska M, Calbecka M, Gajkowska-Kulik J, Gadomska G, Kielbinski M, Ejduk A, Kata D, Grosicki S, Wierzbowska A, Kyrcz-Krzemien S, Warzocha K, Kuliczkowski K, Skotnicki A, Holowiecki J, Jedrzejczak WW, Haus O.

Blood. 2016 Jan 21;127(3):360-2. doi: 10.1182/blood-2015-08-662130. No abstract available.

PMID:
26567156
13.

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G; Study Alliance Leukemia..

Biol Blood Marrow Transplant. 2016 Mar;22(3):462-9. doi: 10.1016/j.bbmt.2015.10.023.

PMID:
26551637
14.

Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.

Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, Hospital MA, Tamburini J, Delabesse E, Manenti S, Sarry JE, Récher C.

Blood. 2016 Feb 18;127(7):882-92. doi: 10.1182/blood-2015-05-646497.

PMID:
26286850
15.

DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.

Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.

Biol Blood Marrow Transplant. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.2015.07.030.

PMID:
26234722
16.

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

Wu H, Hu C, Wang A, Weisberg EL, Wang W, Chen C, Zhao Z, Yu K, Liu J, Wu J, Nonami A, Wang L, Wang B, Stone RM, Liu S, Griffin JD, Liu J, Liu Q.

Leukemia. 2016 Mar;30(3):754-7. doi: 10.1038/leu.2015.175. No abstract available.

17.

Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.

Fathi AT, Lin WM, Durazzo T, Piris A, Sadrzadeh H, Bernardo L, Borger DR, McAfee SL, Kroshinsky D, Chen YB.

J Clin Oncol. 2016 Mar 10;34(8):e70-2. doi: 10.1200/JCO.2013.50.7582. No abstract available.

PMID:
25024084
Items per page

Supplemental Content

Loading ...
Support Center